AU2001253255A1 - Compositions and methods for inhibiting gene expression - Google Patents

Compositions and methods for inhibiting gene expression

Info

Publication number
AU2001253255A1
AU2001253255A1 AU2001253255A AU5325501A AU2001253255A1 AU 2001253255 A1 AU2001253255 A1 AU 2001253255A1 AU 2001253255 A AU2001253255 A AU 2001253255A AU 5325501 A AU5325501 A AU 5325501A AU 2001253255 A1 AU2001253255 A1 AU 2001253255A1
Authority
AU
Australia
Prior art keywords
compositions
methods
gene expression
inhibiting gene
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253255A
Inventor
Kenneth E. Palmer
Gregory P. Pogue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Large Scale Biology Corp
Original Assignee
Large Scale Biology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Large Scale Biology Corp filed Critical Large Scale Biology Corp
Publication of AU2001253255A1 publication Critical patent/AU2001253255A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
AU2001253255A 2000-04-07 2001-04-04 Compositions and methods for inhibiting gene expression Abandoned AU2001253255A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54557400A 2000-04-07 2000-04-07
US09/545,574 2000-04-07
PCT/US2001/011436 WO2001077350A2 (en) 2000-04-07 2001-04-04 Compositions and methods for inhibiting gene expression

Publications (1)

Publication Number Publication Date
AU2001253255A1 true AU2001253255A1 (en) 2001-10-23

Family

ID=24176765

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253255A Abandoned AU2001253255A1 (en) 2000-04-07 2001-04-04 Compositions and methods for inhibiting gene expression

Country Status (2)

Country Link
AU (1) AU2001253255A1 (en)
WO (1) WO2001077350A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586661B1 (en) 1997-06-12 2003-07-01 North Carolina State University Regulation of quinolate phosphoribosyl transferase expression by transformation with a tobacco quinolate phosphoribosyl transferase nucleic acid
WO2002059257A2 (en) * 2000-10-31 2002-08-01 Commonwealth Scientific And Industrial Research Organisation Method and means for producing barley yellow dwarf virus resistant cereal plants
AU2002368202B2 (en) 2001-11-02 2008-06-05 Insert Therapeutics, Inc Methods and compositions for therapeutic use of RNA interference
US20040009946A1 (en) 2002-05-23 2004-01-15 Ceptyr, Inc. Modulation of PTP1B expression and signal transduction by RNA interference
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
AU2002951347A0 (en) * 2002-09-09 2002-09-26 Benitec Australia Ltd Genetic silencing
WO2004091634A1 (en) 2003-04-07 2004-10-28 Glycogenesys, Inc. Composition and uses of galectin antagonists
CA2561221C (en) 2004-03-26 2016-09-20 Curis, Inc. Rna interference modulators of hedgehog signaling and uses thereof
EP2248529B1 (en) 2004-04-05 2016-01-27 The Regents of The University of California NKG2D antibodies for use in the treatment of autoimmune or inflammatory diseases
US7456151B2 (en) 2004-07-14 2008-11-25 University Of Utah Research Foundation Promoting angiogenesis with netrin1 polypeptides
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
EP1866414B9 (en) 2005-03-31 2012-10-03 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
WO2008127710A2 (en) 2007-04-13 2008-10-23 Dana Farber Cancer Institute Methods for treating cancer resistant to erbb therapeutics
AU2008256644B2 (en) 2007-05-24 2014-07-03 The United States Government As Represented By The Department Of Veterans Affairs Intranuclear protein transduction through a nucleoside salvage pathway
BRPI0911332A2 (en) 2008-04-04 2019-09-24 Calando Pharmaceuticals Inc compositions and use of epas1 inhibitors
US8470792B2 (en) 2008-12-04 2013-06-25 Opko Pharmaceuticals, Llc. Compositions and methods for selective inhibition of VEGF
IT1398977B1 (en) 2009-06-25 2013-03-28 Icgeb ANTI-PANT AGENT SPECIFIC FOR CEREBRAL CANCERS WITH RECQ1 SUPPRESSION MECHANISM
GB201103167D0 (en) 2011-02-24 2011-04-06 Isis Innovation Gene silencing
CN104797593B (en) 2012-09-28 2020-05-08 北卡罗来纳-查佩尔山大学 AAV vectors targeting oligodendrocytes
AU2015333689A1 (en) 2014-10-14 2017-05-25 The Regents Of The University Of California Use of CDK9 and BRD4 inhibitors to inhibit inflammation
WO2016081811A1 (en) 2014-11-21 2016-05-26 The University Of North Carolina At Chapel Hill Aav vectors targeted to the central nervous system
CN107531774B (en) 2015-02-06 2021-12-14 北卡罗来纳大学查珀尔希尔分校 Optimized human coagulation factor VIII gene expression cassette and application thereof
WO2016140921A1 (en) 2015-03-02 2016-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an il-33 antagonist
CN114652735A (en) 2016-07-27 2022-06-24 凯斯西储大学 Compounds and methods for promoting myelination
US20200040345A1 (en) 2016-12-08 2020-02-06 Case Western Reserve University Methods and compositions for enhancing functional myelin production
WO2020160508A1 (en) 2019-01-31 2020-08-06 Oregon Health & Science University Methods for using transcription-dependent directed evolution of aav capsids

Also Published As

Publication number Publication date
WO2001077350A3 (en) 2002-08-08
WO2001077350A2 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
AU2001253255A1 (en) Compositions and methods for inhibiting gene expression
AU2001280968A1 (en) Compositions and methods for directed gene assembly
AU2625501A (en) Compositions and methods for gene silencing
AU2778801A (en) Antisense compositions and methods
AU2001285143A1 (en) Methods and compositions for targeted delivery
IL151781A0 (en) Methods and compositions for rna interference
AU2001258771A1 (en) -secretase inhibitors
AU2002357119A1 (en) Mitocidal compositions and methods
AU2001271720A1 (en) Methods and compositions for determining gene function
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2002225894A1 (en) Methods and compositions for the control of coccidiosis
AU2002236626A1 (en) Compositions and methods for treating hyperpigmentation
MXPA02003232A (en) Compositions and methods for altering gene expression.
AU2001238485A1 (en) Methods and compositions for gene delivery
AU2002357748A1 (en) Osteopontin-related compositions and methods
AU2001233932A1 (en) Method and composition
AU2002239258A1 (en) Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon
AU6094200A (en) Nor gene compositions and methods for use thereof
AU2001264247A1 (en) GASC1 gene
AU2756301A (en) Compositions comprising genome segments and methods of using the same
AU2002351200A1 (en) Compositions and methods for inhibiting prenyltransferases
AU2002310046A1 (en) Compositions and methods for inhibiting metastasis
AU2001247444A1 (en) Erbeta-mediated gene expression
AU2001283226A1 (en) Methods and compositions for inhibiting rad51
EP1163340A4 (en) Compositions and methods for the modification of gene expression